Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Cell Genesys55 enrolled

Overview

The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Acute Myelogenous Leukemia

Interventions

GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)BIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Initial diagnosis of de novo AML with no preexisting hematologic dysplasia for more than 3 months. * No prior therapy except leukapheresis or less than 72 hours of hydroxyurea. Exclusion Criteria: * Prior myelodysplastic disorder, or treatment-related leukemia. * Prior myeloproliferative disease. * Acute promyelocytic leukemia (APL). * Prior chemotherapy for a malignant or nonmalignant disorder.

Locations (4)

University of California, San Francisco

San Francisco, California, United States

University of Chicago

Chicago, Illinois, United States

Johns Hopkins University

Baltimore, Maryland, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.